Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan [6][34]. - Jintou Shengyuan aims to enhance the operational efficiency of provincial government industrial funds and support the establishment of a modern industrial system in Zhejiang [34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%. It is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to reach approximately 10 billion yuan in 2024 and continue to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of long-chain dicarboxylic acids through biological methods since 2003, breaking the monopoly of chemical synthesis [7]. - Ginkgo Bioworks, established in 2008, has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector, highlighting the need for companies to leverage AI and automation to enhance research and development efficiency [15][16]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research services with product offerings [15].
免费获取“合成生物学行业报告”!技术路径、产业布局与投资逻辑等全解(可获取PDF全文)
synbio新材料·2026-03-13 06:28